<http://webisa.webdatacommons.org/431989809>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/118398001>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/431989809> .
<http://webisa.webdatacommons.org/431989809>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<biospectrumasia.com> .
<http://webisa.webdatacommons.org/431989809>	<http://www.w3.org/ns/prov#value>	"In cases where license agreements are concluded based on the terms of this agreement, Santen will be able to apply in the ophthalmologic field any compounds for which efficacy, safety and other data have been accumulated, and as a result, can expect to enhance its ophthalmology pipeline and reduce the time it takes to bring the respective compounds to phase I clinical development." .